# A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer

> **NCT03348527** · PHASE2 · COMPLETED · sponsor: **Lidds AB** · enrollment: 61 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 2-Hydroxyflutamide Depot

## Key facts

- **NCT ID:** NCT03348527
- **Lead sponsor:** Lidds AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-12
- **Primary completion:** 2020-10-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2020-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03348527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03348527, "A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03348527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*